Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	585.15B +92.6%
Revenue (ttm)	213.81B +27.5%
Net Income	35.33B
EPS	2,498.04
Shares Out	13.09M
PE Ratio	17.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,318
Open	45,050
Previous Close	44,700
Day's Range	44,650 - 48,600
52-Week Range	27,550 - 72,700
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 3, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 425
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940